Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC versus ECC plus pravastatin for advanced gastric cancer
NL-OMON27982Phase 2Recruiting
- Sponsor
- Not applicable
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pravastatin in gastric adenocarcinoma (2 arms), sponsored by Not applicable. Primary endpoint: Progression-free survival rate at 6 months. Started Feb 2005; status: recruiting.
02
Drugs
pravastatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NL-OMON27982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27982.